HK Stock Market Move | BIODLINK-B(01875) rose more than 9% in trading, Wuxi XDC CEO Li Jincai takes over as executive director and chairman of the board

BIODLINK-B(01875) rose more than 9% during the trading session, and as of the time of writing, it is up 6.77% at 4.89 Hong Kong dollars, with a turnover of 19.571 million Hong Kong dollars. On the news front, Dongya Pharmaceutical announced several management changes. Li Jincai has been appointed as an executive director, chairman of the board, chairman of the nomination committee, chairman of the strategic and ESG committee, and member of the compensation committee, effective from April 29. It is reported that Li Jincai is the CEO of WUXI XDC (02268). Public information shows that in March of this year, WUXI XDC completed a cash tender offer for Dongya Pharmaceutical. Guotou Securities International pointed out that Dongya Pharmaceutical has achieved a magnificent transformation, turning from a traditional pharmaceutical company into a leading enterprise in the CDMO track. With the deep synergy and integration with Pharmaron, the company's future CDMO business is expected to continue to grow steadily, further consolidating its industry position. Future CDMO order prices are expected to increase further.